301301.SZ
川宁生物
SZSE · C 制造业 · CN
CNY 8.62
−4.43%Year over year
Reported trailing growth
- Revenue
- -20.2%
- EBITDA
- —
- EBIT
- -53.9%
- EPS
- -56.1%
- Free cash flow
- -68.8%
- Operating cash flow
- -62.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.5%
- EBITDA
- +11.9%
- EBIT
- +20.6%
- Net income
- +23.2%
- EPS
- +17.4%
- Free cash flow
- -11.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026